By: Dr. Fabiano de Abreu Agrela Rodrigues (Ehlers-Danlos Specialist)
Discussing Ehlers-Danlos Syndrome (EDS) requires care because we are dealing with a heterogeneous group of conditions, not a single, uniform entity. Reducing EDS to the idea that it “causes miscarriages” is an inadequate simplification that can generate unnecessary fear and obscure the much more complex clinical reality. The topic deserves to be addressed with nuance, especially when it involves reproduction, obstetric risk, and genetic counseling.
One of the first points that needs to be clarified is that EDS functions, in practice, as a spectrum. There are different subtypes, with distinct manifestations and severities, ranging from milder forms to variants associated with significant vascular fragility and higher maternal-fetal risk. This means that any discussion about pregnancy in EDS should begin with the most important question: which subtype are we talking about? Without this distinction, the debate becomes imprecise and potentially misleading.
In obstetrics, the temptation to turn risk into the rule is great, but that’s precisely where the mistake lies. Yes, there are reports of miscarriage, ectopic pregnancy, and premature birth in people with EDS. But that doesn’t mean these complications occur in most cases. In many situations, the pregnancy progresses favorably, although it may require closer monitoring, planning, and multidisciplinary follow-up. The difference between “it can happen” and “it will happen” is enormous—and in medicine, that difference is crucial.
It is also necessary to recognize that EDS overlaps with other connective tissue phenotypes and syndromes, such as the Marfanoid phenotype and Marfan syndrome itself. In some people, clinical features seem to blur diagnostic boundaries: long limbs, hypermobility, skeletal abnormalities, and systemic signs may suggest overlap between distinct conditions. This is not a semantic detail; it is a real problem of classification, diagnosis, and follow-up. When the diagnosis is imprecise, the risk is both underestimating and overestimating the severity of the case.
In the context of pregnancy, individualization is essential. A patient with joint hypermobility and mild symptoms should not be treated as if she automatically has the same risk profile as a patient with vascular EDS. Responsible medicine does not work with stereotypes, but rather with risk stratification based on subtype, clinical history, cardiovascular findings, and obstetric history. It is precisely this approach that avoids both trivialization and alarmism.
There is also an often-neglected aspect: the emotional impact of simplified messages. When someone with EDS or suspected EDS reads that “the disease causes miscarriages,” the immediate interpretation may be one of guilt, fear, or fatalism. This is especially unfair in a context where the person is already dealing with chronic symptoms, diagnostic uncertainties, and often years of clinical invalidation. Medical and scientific communication needs to be accurate without being cruel, clear without being reductionist.
The most sensible approach is to state that EDS can increase pregnancy risks in certain subtypes and situations, but does not, by itself, define a negative reproductive outcome. Furthermore, the phenotype can overlap with other collagenopathies, requiring specialized evaluation. Instead of perpetuating absolute statements, we should insist on language that respects biological variability and the concrete experience of patients. In healthcare, nuance is not argumentative weakness; it is a sign of clinical maturity.
Ultimately, the debate about EDS and pregnancy reveals a broader lesson: complex diseases cannot be contained in slogans. When medicine is reduced to simplistic maxims, precision, humanity, and the opportunity for adequate care are lost. Treating Ehlers-Danlos Syndrome as a spectrum, and not as a caricature, is the first step towards discussing pregnancy with intellectual and ethical responsibility.
